Novartis AG
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
678 / 1328
Position in country
267 / 449
Return on Assets, %
7.7
-2.7
Net income margin, %
22.4
2.8
EBITDA margin, %
39.8
10.8
Debt to Equity, %
56.4
19.2
Intangible assets and goodwill, %
50.2
3.6
Revenue CAGR 3Y, %
-2.3
8.5
Total Equity change 1Y, %
-21.4
0
Revenue Y, % chg
7.2
0.5
P/E
22.7
22.7
P/BV
4
1.5
P/S
4.3
2.3
EV/S
4.7
2.4
EV/EBITDA
10.2
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
19.8
51.3
Forward P/E
12.7
15.6
Dividend Yield, %
3.9
1.7
Forward Dividend Yield, %
3.9
0.2
Expected dividend per share
3.7
0
Payout Ratio, %
82.2
30.3
Dividend Ex Date
2024-03-07
Competitors
Ranks
-
Novo Nordisk A/S
00%
-
Vifor Pharma AG
00%
-
AstraZeneca PLC
00%
-
Eli Lilly and Co
00%
-
Roche Holding AG
00%
-
Dottikon Es Holding AG
00%
-
Novartis AG
00%
-
Sandoz Group AG
00%
-
Johnson & Johnson
00%
-
Merck & Co Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Switzerland
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
207246.6
Ticker
NVS.N
ISIN
US66987V1098
IPO date
2001-05-07
Availability on Russian exchanges
Yes
Reporting for
2024-01-31
Date fact. publication of reports
2023-12-31
Company Description
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: